Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier

Rui Yang, Wei Wei Li, Bang H. Hoang, Hansoo Kim, Debabrata Banerjee, Albert Kheradpour, John H. Healey, Paul A. Meyers, Joseph R. Bertino, Richard Gorlick

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Methotrexate (MTX) uptake is mediated by the reduced folate carrier (RFC). Defective drug uptake in association with decreased RFC expression is a common mechanism of MTX resistance in many tumor types. Heavy promoter methylation was previously identified as a basis for the complete silencing of RFC in MDA-MB-231 breast cancer cells, its role and prevalence in RFC transcription regulation are, however, not widely studied. Methods: In the current study, RFC promoter methylation was assessed using methylation specific PCR in a panel of malignant cell lines (n = 8), including MDA-MB-231, and M805, a MTX resistant cell line directly established from the specimen of a patient with malignant fibrohistocytoma, whom received multiple doses of MTX. A quantitative approach of real-time PCR for measuring the extent of RFC promoter methylation was developed, and was validated by direct bisulfite genomic sequencing. RFC mRNA levels were determined by quantitative real-time RT-PCR and were related to the extent of promoter methylation in these cell lines. Results: A partial promoter methylation and RFC mRNA down-regulation were observed in M805. Using the quantitative approach, a reverse correlation (correlation coefficient = -0.59, p < 0.05) was identified between the promoter methylation and RFC mRNA levels in this a panel of malignant cell lines. Conclusion: This study further suggests that promoter methylation is a potential basis for MTX resistance. The quantitative correlation identified in this study implies that promoter methylation is possibly a mechanism involved in the fine regulation of RFC transcription.

Original languageEnglish (US)
Article number124
JournalBMC Cancer
Volume8
DOIs
StatePublished - May 1 2008

Fingerprint

Reduced Folate Carrier Protein
Methylation
Messenger RNA
Methotrexate
Cell Line
Real-Time Polymerase Chain Reaction
Down-Regulation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. / Yang, Rui; Li, Wei Wei; Hoang, Bang H.; Kim, Hansoo; Banerjee, Debabrata; Kheradpour, Albert; Healey, John H.; Meyers, Paul A.; Bertino, Joseph R.; Gorlick, Richard.

In: BMC Cancer, Vol. 8, 124, 01.05.2008.

Research output: Contribution to journalArticle

Yang, R, Li, WW, Hoang, BH, Kim, H, Banerjee, D, Kheradpour, A, Healey, JH, Meyers, PA, Bertino, JR & Gorlick, R 2008, 'Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier', BMC Cancer, vol. 8, 124. https://doi.org/10.1186/1471-2407-8-124
Yang, Rui ; Li, Wei Wei ; Hoang, Bang H. ; Kim, Hansoo ; Banerjee, Debabrata ; Kheradpour, Albert ; Healey, John H. ; Meyers, Paul A. ; Bertino, Joseph R. ; Gorlick, Richard. / Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. In: BMC Cancer. 2008 ; Vol. 8.
@article{e3d6e3e7f75446db8de3e44ebba6ee30,
title = "Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier",
abstract = "Background: Methotrexate (MTX) uptake is mediated by the reduced folate carrier (RFC). Defective drug uptake in association with decreased RFC expression is a common mechanism of MTX resistance in many tumor types. Heavy promoter methylation was previously identified as a basis for the complete silencing of RFC in MDA-MB-231 breast cancer cells, its role and prevalence in RFC transcription regulation are, however, not widely studied. Methods: In the current study, RFC promoter methylation was assessed using methylation specific PCR in a panel of malignant cell lines (n = 8), including MDA-MB-231, and M805, a MTX resistant cell line directly established from the specimen of a patient with malignant fibrohistocytoma, whom received multiple doses of MTX. A quantitative approach of real-time PCR for measuring the extent of RFC promoter methylation was developed, and was validated by direct bisulfite genomic sequencing. RFC mRNA levels were determined by quantitative real-time RT-PCR and were related to the extent of promoter methylation in these cell lines. Results: A partial promoter methylation and RFC mRNA down-regulation were observed in M805. Using the quantitative approach, a reverse correlation (correlation coefficient = -0.59, p < 0.05) was identified between the promoter methylation and RFC mRNA levels in this a panel of malignant cell lines. Conclusion: This study further suggests that promoter methylation is a potential basis for MTX resistance. The quantitative correlation identified in this study implies that promoter methylation is possibly a mechanism involved in the fine regulation of RFC transcription.",
author = "Rui Yang and Li, {Wei Wei} and Hoang, {Bang H.} and Hansoo Kim and Debabrata Banerjee and Albert Kheradpour and Healey, {John H.} and Meyers, {Paul A.} and Bertino, {Joseph R.} and Richard Gorlick",
year = "2008",
month = "5",
day = "1",
doi = "10.1186/1471-2407-8-124",
language = "English (US)",
volume = "8",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier

AU - Yang, Rui

AU - Li, Wei Wei

AU - Hoang, Bang H.

AU - Kim, Hansoo

AU - Banerjee, Debabrata

AU - Kheradpour, Albert

AU - Healey, John H.

AU - Meyers, Paul A.

AU - Bertino, Joseph R.

AU - Gorlick, Richard

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Background: Methotrexate (MTX) uptake is mediated by the reduced folate carrier (RFC). Defective drug uptake in association with decreased RFC expression is a common mechanism of MTX resistance in many tumor types. Heavy promoter methylation was previously identified as a basis for the complete silencing of RFC in MDA-MB-231 breast cancer cells, its role and prevalence in RFC transcription regulation are, however, not widely studied. Methods: In the current study, RFC promoter methylation was assessed using methylation specific PCR in a panel of malignant cell lines (n = 8), including MDA-MB-231, and M805, a MTX resistant cell line directly established from the specimen of a patient with malignant fibrohistocytoma, whom received multiple doses of MTX. A quantitative approach of real-time PCR for measuring the extent of RFC promoter methylation was developed, and was validated by direct bisulfite genomic sequencing. RFC mRNA levels were determined by quantitative real-time RT-PCR and were related to the extent of promoter methylation in these cell lines. Results: A partial promoter methylation and RFC mRNA down-regulation were observed in M805. Using the quantitative approach, a reverse correlation (correlation coefficient = -0.59, p < 0.05) was identified between the promoter methylation and RFC mRNA levels in this a panel of malignant cell lines. Conclusion: This study further suggests that promoter methylation is a potential basis for MTX resistance. The quantitative correlation identified in this study implies that promoter methylation is possibly a mechanism involved in the fine regulation of RFC transcription.

AB - Background: Methotrexate (MTX) uptake is mediated by the reduced folate carrier (RFC). Defective drug uptake in association with decreased RFC expression is a common mechanism of MTX resistance in many tumor types. Heavy promoter methylation was previously identified as a basis for the complete silencing of RFC in MDA-MB-231 breast cancer cells, its role and prevalence in RFC transcription regulation are, however, not widely studied. Methods: In the current study, RFC promoter methylation was assessed using methylation specific PCR in a panel of malignant cell lines (n = 8), including MDA-MB-231, and M805, a MTX resistant cell line directly established from the specimen of a patient with malignant fibrohistocytoma, whom received multiple doses of MTX. A quantitative approach of real-time PCR for measuring the extent of RFC promoter methylation was developed, and was validated by direct bisulfite genomic sequencing. RFC mRNA levels were determined by quantitative real-time RT-PCR and were related to the extent of promoter methylation in these cell lines. Results: A partial promoter methylation and RFC mRNA down-regulation were observed in M805. Using the quantitative approach, a reverse correlation (correlation coefficient = -0.59, p < 0.05) was identified between the promoter methylation and RFC mRNA levels in this a panel of malignant cell lines. Conclusion: This study further suggests that promoter methylation is a potential basis for MTX resistance. The quantitative correlation identified in this study implies that promoter methylation is possibly a mechanism involved in the fine regulation of RFC transcription.

UR - http://www.scopus.com/inward/record.url?scp=44149098042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44149098042&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-8-124

DO - 10.1186/1471-2407-8-124

M3 - Article

C2 - 18452618

AN - SCOPUS:44149098042

VL - 8

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 124

ER -